반응식
[CH2:1]([C:3]1[N:13](CC2C=CC3/C(=C(/C)\C#N)/C4C=CC=CC=4CCC=3C=2)[C:6]2=[N:7][C:8]([CH3:12])=[CH:9][C:10]([CH3:11])=[C:5]2[N:4]=1)[CH3:2].OCC1C=CC2/C(=C(/C)\C#N)/C3C=CC=CC=3CCC=2C=1>>[CH2:1]([C:3]1[NH:13][C:6]2=[N:7][C:8]([CH3:12])=[CH:9][C:10]([CH3:11])=[C:5]2[N:4]=1)[CH3:2]참가 물질
3
반응물 2
생성물 1
실험 절차
[step 1] (Z)-2-[2-(2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene]propiononitrile (376 mg, 68%) was obtained in the same manner as in step 1 of Example 36, using (Z)-2-(2-hydroxymethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)propiononitrile (350 mg, 1.3 mmol) obtained in Reference Example 6 and 2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine (349 mg, 2.0 mmol) instead of 5-chloro-2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridine.
출처 및 근거
- ORD 기록
- ord-a977f7ef3f4544a393334aa25bf440ca
- 출처 데이터셋
- uspto-grants-2012_08
- 특허 번호
- US08242151B2
연결된 노트
불러오는 중…